NASH Biomarkers Market by GENFIT; Gilead; AstraZeneca; Novartis AG; Bristol-Myers Squibb

The global Non-alcoholic steatohepatitis biomarkers market size was valued at USD 200.04 million in 2016 and is expected to witness a CAGR of 30.1% during the forecast period.

The global Non-Alcoholic Steatohepatitis Biomarkers Market size is expected to reach USD 2.09 billion by 2025, at a CAGR of 30.1% according to a new report by Grand View Research, Inc. Increasing incidence of chronic liver diseases is expected to propel the demand for NASH biomarkers over the forecast period. The National Health and Nutrition Examination Survey recently found that approximately 30% of Nonalcoholic Fatty Liver Diseases (NAFLD) occurred in the U.S. alone. This disease remains undiagnosed, as a liver can remain fatty without any change in its function. However, it can progress into a serious condition, known as nonalcoholic steatosis that may result in liver failure. NASH is characterized by inflammation and irreversible cell death.

Rising demand for non-invasive diagnostic tools for detection of NASH is another driver of market. Traditionally, liver biopsy is performed to diagnose NAFLD and its degenerative condition, that is, NASH. This technique is expensive and invasive in nature. This disadvantage has led to the development of noninvasive and cost-efficient diagnostic techniques such as biomarker tests. It is observed that many key companies spent significantly on research and development activities to introduce novel biomarker tests. These factors are expected to propel NASH biomarkers market in the coming years.

The drug manufacturers are focusing on tapping unmet medical needs for treatment of NASH to capture additional market share. Strategic collaborations, expansion in developing geographies, and technological advancements are some of the key strategies adopted by existing market players.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/non-alcoholic-steatohepatitis-nash-biomarkers-market

Further Key Findings From the Study Suggest:

• Serum biomarkers held majority of the revenue share as of 2016 owing to its high efficacy in NASH diagnosis
• Gamma-glutamyl transferase is the serum biomarker that is usually higher in patients with fatty liver diseases, resulting in liver failure
• Increasing list of patients awaiting liver transplantation is a major contributing factor for the growing demand of noninvasive biomarker tests over the forecast period
• Pharmaceutical and contract research industry dominate the end-use segment owing to ample availability of R&D funding and ongoing research projects for the development NASH drugs
• Industry participants are focusing on development of cost-effective solutions, thereby increasing R&D activities for development of novel technologies